BioSpace News Archive

Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing and commercializing treatments for potentially life-threatening food allergies, today announced it will present new data from the clinical trial program for PALFORZIA™ [Peanut (Arachis hypogaea) Allergen Powder-dnfp], the first-ever peanut allergy treatment approved by the U.S. Food and Drug Administration (FDA).

Bone Solutions Inc., an orthobiologics technology company located in Colleyville, TX, announces it has surpassed 1,000 cases implanting OsteoCrete® in various orthopedic applications.

INCLINE VILLAGE, Nev. , Feb. 25, 2020 /PRNewswire/ -- PDL BioPharma, Inc. (“PDL” or the “Company”) (Nasdaq: PDLI) announces that Dominique Monnet , PDL’s president and chief executive officer, will present at the Cowen and Company 40 th Annual Health Care Conference on Tuesday, March 3, 2020 at 10:40 a.m. Eastern time ( 7:40 a.m. Pacific time ). The conference is being h

The world’s first FDA-cleared four-mode radiofrequency microneedling system allows practitioners to deliver a variety of customized treatments on single device

Surglogs, Inc., the first software company to offer a full suite of automated regulatory compliance solutions for ambulatory surgery centers and hospitals, announced that healthcare industry veteran and ambulatory accreditation expert Victoria Samper has joined the Company as Director of Regulatory Compliance.

I-Mab, a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical needs, particularly cancers and autoimmune disorders, announced its participation in the following conferences in March.

CONMED Corporation announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share, payable on April 6, 2020 to all shareholders of record as of March 16, 2020.

The newly designed Fox Trial Finder connects volunteers to hundreds of actively recruiting Parkinson’s clinical studies

Despite demand and availability, patients lack awareness of pharma-driven services to support medication access and adherence

Allakos Inc. reported financial results for the fourth quarter and full year ended December 31, 2019 and provided an update of its ongoing and planned development activities.